TICKERNERD
Menu
CYTKCYTKHealthcare · Biotechnology

CYTK Stock Forecast: Cytokinetics, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$64
+2.90% on the day

The 22 Wall Street analysts covering Cytokinetics, Inc. hold a median 12-month price target of $106 — +65.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 3 Nov 2026 — in the lower half.

Market cap
$8.7B
Ticker Nerd rank
48/ 100
Median analyst target
$106
Analysts covering
22
Revenue$28.6M−57.1% y/y
Operating income−$179.2M
Net income−$198.8M
Free cash flow−$164.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.6%
1M
−2.3%
YTD
+0.9%
1Y
+7.5%
From 52W high
−26.5%
From 52W low
+8.3%
$59
$87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CYTK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cytokinetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
48/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
89
Volatility
77
Value
71
Momentum
63
Accruals
48
Quality
45
Growth
32
Size
17
Issuance
10

Revisions (89): Analysts have, on balance, been raising their forecasts.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CYTK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CYTK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26CYTKHigh $140Median $106Low $81

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
20 Buy2 Hold0 Sell
Low $81Median $106High $140

The green dot is the last close — the median target sits +65.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
19 Oct 2026HC Wainwright & Co.ReiteratesBuy$140
16 Oct 2026William BlairInitiatesOutperform—
8 Oct 2026RBC CapitalMaintainsOutperform$112 → $113
8 Oct 2026RBC CapitalMaintainsOutperform—
31 Aug 2026HC Wainwright & Co.ReiteratesBuy—
31 Aug 2026HC Wainwright & Co.ReiteratesBuy$140
13 Aug 2026BarclaysMaintainsOverweight$95 → $110
13 Aug 2026BarclaysMaintainsOverweight—
13 Aug 2026JP MorganMaintainsOverweight$97 → $103
13 Aug 2026JP MorganMaintainsOverweight—
10 Aug 2026Truist SecuritiesMaintainsBuy$106 → $112
10 Aug 2026Truist SecuritiesMaintainsBuy—
7 Aug 2026CitizensMaintainsMarket Outperform—
7 Aug 2026CitizensMaintainsMarket Outperform$105 → $110
7 Aug 2026NeedhamMaintainsBuy—
7 Aug 2026NeedhamMaintainsBuy$102 → $112
7 Aug 2026RBC CapitalMaintainsOutperform$117 → $112
7 Aug 2026RBC CapitalMaintainsOutperform—
7 July 2026RBC CapitalMaintainsOutperform$119 → $117
7 July 2026RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CYTK appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CYTK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Cytokinetics, Inc. returned +7.5% against +12.9% for the S&P 500, dividends included.

CYTK vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26CYTKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CYTK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Cytokinetics, Inc. (CYTK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.5×

Cheaper than 93% of US stocks

Price / sales
129.0×

Cheaper than 3% of US stocks

Price / book
−47.4×

Cheaper than 99% of US stocks

EV / EBITDA
−12.8×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
−57.1%

Higher than 5% of US stocks

Earnings growth (YoY)
−57.1%

Higher than 9% of US stocks

Gross margin
80.5%

Higher than 91% of US stocks

Operating margin
−626.0%

Higher than 7% of US stocks

Net margin
−372.5%

Higher than 1% of US stocks

Returns & dividend
Return on equity
119.0%

Higher than 97% of US stocks

Return on assets
−28.1%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cytokinetics, Inc. (CYTK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cytokinetics, Inc. has a market value of $8.7B and an enterprise value of $8.9B.

  • Revenue in the twelve months to 30 June 2026: $67.7M. The latest quarter shrank 57.1% year on year.

  • Net income over the same four quarters: −$894.0M, a −1321.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−7.22.

  • Free cash flow in the twelve months to 30 June 2026: −$580.7M.

  • Shares outstanding: 138.8M.

  • Trailing P/E: −9.5×; forward P/E: −14.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cytokinetics, Inc. employs 673 people — $101K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Nov 2026

Data provided by Twelve Data

Peers

CYTK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CYTKCytokinetics, Inc.$8.7B48
IBRXImmunityBio, Inc.$8.7B62
CORTCorcept Therapeutics, Inc.$8.8B69
PTGXProtagonist Therapeutics, Inc.$8.9B98
ARWRArrowhead Pharmaceuticals, Inc.$8.3B54
KRYSKrystal Biotech, Inc.$9.0B89
MDGLMadrigal Pharmaceuticals, Inc.$9.1B79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cytokinetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CYTK news & analysis

Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 4 Nov 2026positive

Cytokinetics reported third-quarter 2026 financial results and a business update, including $44.5 million in MYQORZO (aficamten) net product revenue. The company said it expects to submit a supplemental NDA for aficamten in non-obstructive HCM in Q4 2026 and an EU Type II variation in early 2027, and reported approximately $1.6 billion in cash, cash equivalents and investments as of September 30, 2026.

Why it matters — The update provides CYTK watchers with product revenue, planned regulatory submissions, and the company's reported cash and investment position.

Cytokinetics to Participate in November Investor Conferences

GlobeNewsWire · 3 Nov 2026neutral

Cytokinetics announced that members of its management team will participate in investor conferences in November.

Why it matters — The conferences provide opportunities for CYTK watchers to hear from company management.

Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

GlobeNewsWire · 2 Nov 2026positive

Cytokinetics announced three upcoming presentations—two late-breaking oral abstracts and one poster—at the HCMS Scientific Sessions, held with the American Heart Association Scientific Sessions in Chicago on November 6, 2026.

Why it matters — The presentations will share company-related information at a medical meeting relevant to hypertrophic cardiomyopathy.

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research · 28 Oct 2026positive

Zacks Investment Research says Cytokinetics has a combination of two key ingredients associated with a likely earnings beat in its upcoming report.

Why it matters — CYTK watchers may note the article's expectation of a potential earnings beat ahead of the upcoming report.

Baron Health Care Fund Q3 2026 Top Contributors And Detractors

Seeking Alpha · 26 Oct 2026neutral

The excerpt says TMO’s organic growth was 5%, 200 basis points above consensus, and management raised full-year organic growth guidance. MTD’s local-currency sales grew 6%, above prior guidance of 3%, while TEVA management raised guidance for all three brands.

Why it matters — The excerpt provides no direct information about Cytokinetics, so it offers little company-specific context for a CYTK watcher.

FAQ

Frequently asked questions about CYTK stock

What is the CYTK stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Cytokinetics, Inc. have a median 12-month price target of $106, with estimates ranging from $81 to $140. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CYTK stock a buy right now?

Of the 22 analysts covering Cytokinetics, Inc., 20 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cytokinetics, Inc. 48 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CYTK?

As at 3 Nov 2026, Cytokinetics, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (89 of 100).

Will CYTK stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +65.3% from the last close, and Ticker Nerd's factor model ranks Cytokinetics, Inc. 48 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CYTK stock forecast for 2030?

No analyst covering Cytokinetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CYTK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $81 to $140 over the next 12 months.

How has CYTK stock performed over the past year?

Cytokinetics, Inc. returned +7.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cytokinetics, Inc. do?

Cytokinetics, Incorporated is a specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing medicines that target muscle biology. Its current work centers on therapies for cardiac muscle dysfunction, particularly heart conditions in which the heart’s contractile performance is compromised.

What is the latest news on CYTK?

The most recent item we track (GlobeNewsWire, 4 Nov 2026): "Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update". Cytokinetics reported third-quarter 2026 financial results and a business update, including $44.5 million in MYQORZO (aficamten) net product revenue. The company said it expects to submit a supplemental NDA for aficamten in non-obstructive HCM in Q4 2026 and an EU Type II variation in early 2027, and reported approximately $1.6 billion in cash, cash equivalents and investments as of September 30, 2026.

Company

About Cytokinetics, Inc.

Cytokinetics, Incorporated is a specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing medicines that target muscle biology. Its current work centers on therapies for cardiac muscle dysfunction, particularly heart conditions in which the heart’s contractile performance is compromised. The company markets MYQORZO, an oral cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy, and is advancing additional drug candidates such as aficamten for broader hypertrophic cardiomyopathy use and omecamtiv mecarbil for heart failure. Cytokinetics also develops other muscle-directed candidates in clinical-stage programs, reflecting its emphasis on precision treatments for diseases affecting cardiac and skeletal muscle function. Headquartered in South San Francisco, California, Cytokinetics plays a specialized role in the biopharmaceutical market by focusing on muscle performance disorders within cardiovascular medicine.

CEO Mr. Robert I. Blum · 673 employees · United States · https://www.cytokinetics.com